Who
Robert F. Booth
Director
Company insider
Files Form 4 as: Director, Summit Therapeutics; Director, CymaBay Therapeutics; Director, Pharmacyclics.
In numbers
- Trades disclosed
- 65
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 9 Dec 2010
- Last trade
- 2 Jan 2026
- Last filed
- 6 Jan 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 6 Jan 2026 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 | filing |
| 2 Jan 2026filed 6 Jan 2026 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $63K7,180 at $8.76 | filing |
| 2 Jan 2026filed 6 Jan 2026 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 | filing |
| 2 Jan 2026filed 6 Jan 2026 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $63K7,180 at $8.76 | filing |
| 2 Jan 2025filed 6 Jan 2025 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 | filing |
| 2 Jan 2025filed 6 Jan 2025 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $63K6,855 at $9.18 | filing |
| 2 Jan 2024filed 4 Jan 2024 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 | filing |
| 2 Jan 2024filed 4 Jan 2024 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $63K47,651 at $1.32 | filing |
| 3 Jan 2023filed 5 Jan 2023 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 | filing |
| 3 Jan 2023filed 5 Jan 2023 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $55K32,700 at $1.67 | filing |
| 28 Sep 2022filed 3 Oct 2022 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 | filing |
| 28 Sep 2022filed 3 Oct 2022 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,250 | filing |
| 29 Jan 2019filed 31 Jan 2019 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code A | —27,705 at $0.00 | filing |
| 24 Jan 2018filed 26 Jan 2018 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 22 Sep 2017filed 26 Sep 2017 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 28 Jun 2017filed 30 Jun 2017 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 19 Jan 2017filed 23 Jan 2017 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 26 May 2015filed 28 May 2015 | Pharmacyclics | SEC FORM 4 Code D | $2.6M10,000 at $261.25 | filing |
| 26 May 2015filed 28 May 2015 | Pharmacyclicsoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 26 May 2015filed 28 May 2015 | Pharmacyclicsoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.